Sentences with phrase «trial study at»

Through clinical trial studies at The Ohio State University College of Veterinary Medicine.

Not exact matches

The striking example I focused on then was the cancer drug Avastin, developed by Genentech (now Roche)-- which, at the time, had been studied in at least 400 completed human clinical trials for various cancers.

Even the glitteriest of gold - standard clinical trials, for instance, are often undone by a leaden follow - up study that has the nerve to arrive at a different result.

Some retrospective studies and preclinical work have indicated that it might also lower a person's risk of cancer, though at least one clinical trial wasn't able to show that it had any protective effect on esophageal cancer.

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

Woo counters that Maastricht University in the Netherlands is currently conducting a clinical trial studying his company's supplements, which will publish at ClinicalTrials.gov.

Regardless, the study has begun well ahead of the first planned American CRISPR trials, which won regulatory clearance earlier this year (and are being funded by tech billionaire Sean Parker) but are unlikely to begin until 2017 at the University of Pennsylvania.

Studies — including at least one clinical trial with 100 participants — have found that this diet can significantly alter signs of disease, reduce weight and body fat, lower blood pressure, decrease levels of biomarkers associated with cancer, and improve blood - sugar levels.

There are about 120 studies ongoing in Israel, including clinical trials looking at the effects of cannabis on autism, epilepsy, psoriasis, and tinnitus.

While the asthma trial data is just one point, the study's results could go a long way in assuring scientists that information generated through the platform (at least for certain kinds of studies) is on point.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

«[A.I.] can help analyze large data sets from sources such as clinical trials, health records, genetic profiles, and preclinical studies; within this data, it can recognize patterns and trends and develop hypotheses at a much faster rate than researchers alone,» says Deloitte.

Angel is a young ambitious entrepreneur that recieved his MBA from the University of Implimentation and Trial & Error while studying CS at UNM.

A recent study looked at how 244 compounds in 413 clinical trials fared for Alzheimer's disease between 2002 and 2012.

I have personally been inspired by her in many ways, including but not limited to: having the courage to train for a marathon in Port - au - Prince because she had done it first, having the courage to raise my children here through many trials because she had done it first, having the guts to begin to study midwifery at the age of forty - because she had done it at the age of fifty.

At present, there have been no studies on allergenicity and toxicity of Golden Rice, which should be first established in animal feeding trials before feeding trials on humans commence.

Additional laboratories for trials and feasibility studies are being established at different sites around the world.

And Dr Jonathan Scourfield at the Cardiff School of Social Sciences is undertaking a feasibility study for a randomised controlled trial of a training intervention to improve the engagement of fathers in the child protection system.

I may jest, poke fun and otherwise make light of the trials and tribulations of parenthood, but rest assured, I'm always trying to apply the principles I've learned in my positive parenting studies in hopes that at least a majority of the time there will be some level of success.

At The Fertility Center of Las Vegas, each clinical trial is designed as a prospective, randomized study.

Note that the studies used to arrive at these conclusions are mostly randomized controlled trials in which the women who agree to participate are randomly assigned to either epidural or non-epidural pain relief.

Although not directly comparable, our findings are in broad agreement with those from routine data in Scotland that have indicated a positive association between Baby Friendly accreditation, but not certification, and breastfeeding at 1 week of age.17 Our findings reinforce those of Coutinho and colleagues who reported that high exclusive breastfeeding rates achieved in Brazilian hospitals implementing staff training with the course content of the Baby Friendly Hospital Initiative were short - lived and not sustained at home unless implemented in combination with post-natal home visits.35 Similarly in Italy, training of staff with an adapted version of the Baby Friendly course content resulted in high breastfeeding rates at discharge, with a rapid decrease in the days after leaving hospital.36 In contrast, a cluster randomized trial in Belarus (PROBIT) found an association between an intervention modelled on the Baby Friendly Initiative with an increased duration of breastfeeding37 an association also reported from an observational study in Germany.38 Mothers in Belarus stay in hospital post-partum for 6 — 7 days, and in Germany for 5 days, with post-natal support likely to be particularly important in countries where mothers stay in the hospital for a shorter time, with early discharge likely to limit the influence of a hospital - based intervention.

New England Journal of Medicine–NEJM.org NEJM: LEAP Study - Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy NEJM: LEAP - ON Study - Effect of Avoidance on Peanut Allergy after Early Peanut Consumption

One randomized controlled trial comparing home - visited families with control participants who received other community services found a statistically significant difference in mean depressive symptoms at two years post-enrollment, but this contrast was nonsignificant at three years post - enrollment.15 A second study of Early Head Start found no differences in depressive symptoms between intervention and control group participants post-intervention, although a difference was detected at a longer - term follow - up prior to children's enrollment in kindergarten.10 Other randomized controlled trial studies have not found effects of home visitation on maternal depressive symptoms.12, 16,17

Finally, a Finnish trial of universal home visiting by nurses35 and two U.S. programs implemented by master's degree - level mental health or developmental clinicians have found significant effects on a number of important child behavioural problems.36, 37 Additionally, a paraprofessional home visitation program found effects on externalizing and internalizing behaviours at child age 2; however due to the large number of effects measured in this study, replication of the findings is warranted.38

In addition, there was no effect on breastfeeding duration when the pacifier was introduced at 1 month of age.280 A more recent systematic review found that the highest level of evidence (ie, from clinical trials) does not support an adverse relationship between pacifier use and breastfeeding duration or exclusivity.281 The association between shortened duration of breastfeeding and pacifier use in observational studies likely reflects a number of complex factors such as breastfeeding difficulties or intent to wean.281 A large multicenter, randomized controlled trial of 1021 mothers who were highly motivated to breastfeed were assigned to 2 groups: mothers advised to offer a pacifier after 15 days and mothers advised not to offer a pacifier.

«This is the largest randomized trial of any behavioral intervention in children with autism spectrum disorder, and it shows that parent training works,» notes Lawrence Scahill, MSN, PhD, professor of pediatrics at Marcus and Emory School of Medicine, who directed the study.

Although some SIDS experts and policy - makers endorse pacifier use recommendations that are similar to those of the AAP, 272,273 concerns about possible deleterious effects of pacifier use have prevented others from making a recommendation for pacifier use as a risk reduction strategy.274 Although several observational studies275, — , 277 have found a correlation between pacifiers and reduced breastfeeding duration, the results of well - designed randomized clinical trials indicated that pacifiers do not seem to cause shortened breastfeeding duration for term and preterm infants.278, 279 The authors of 1 study reported a small deleterious effect of early pacifier introduction (2 — 5 days after birth) on exclusive breastfeeding at 1 month of age and on overall breastfeeding duration (defined as any breastfeeding), but early pacifier use did not adversely affect exclusive breastfeeding duration.

There has been slight improvement in study reporting or quality, with 44 out of the 73 trials that contributed data (60 %) reporting an approach to allocation concealment that we considered to be at low risk of bias compared to 26 of the 52 trials (50 %) in the previous review (Renfrew 2012b).

The M@NGO Study (Midwives at New Group practice Options): A randomised controlled trial of caseload midwifery care.

The Effect of Skin - to - Skin Contact (Kangaroo Care) Shortly After Birth on the Neurobehavioral Responses of the Term Newborn: A Randomized, Controlled Trial Sari Goldstein Ferber and Imad R. Makhoul Pediatrics 2004; 113; 858 - 865 - DOI: 10.1542 / peds.113.4.858 This information is current as of March 25, 2007 The original version of this article, along with updated information and services, is located at: http://www.pediatrics.org/cgi/content/full/113/4/858 Background: The method of skin - to - skin contact (kangaroo care [KC]-RRB- has shown physiologic, cognitive, and emotional gains for preterm infants; however, KC has not been studied adequately in term newborns.

Declan Devane is a co-author in one of the included trials in this review (Begley 2011) Jane Sandall was and is principal investigator for two studies evaluating models of midwife - led continuity of care (Sandall 2001), and co-investigator on the «Birthplace in England Research Programme», an integrated programme of research designed to compare outcomes of births for women planned at home, in different types of midwifery units, and in hospital units with obstetric services.

The study — led by James Murrough, associate professor of psychiatry and director of the Mood and Anxiety Disorders Program at Mount Sinai — chose the epilepsy drug ezogabine, which was given to 18 patients in a pilot trial.

In a study to be presented Thursday, Jan. 26, in the oral concurrent session at 1:15 p.m. PST, at the Society for Maternal - Fetal Medicine's annual meeting, The Pregnancy Meeting ™, researchers with the Albert Einstein College of Medicine / Montefiore Medical Center in Bronx, New York, will present their findings in a study titled, Comparison of subcuticular suture type in post-cesarean wound complications: a randomized controlled trial.

«This [new] study represents real progress in regenerative medicine and opens the door on new treatment options for people with age - related macular degeneration,» says Pete Coffey at the UCL Institute of Ophthalmology, part of the team who carried out the trial.

As a postdoc, she gained clinical trial experience while studying gastrointestinal tract function at the Mayo Clinic in Rochester, Minnesota, and at Case Western Reserve University in Cleveland, Ohio.

Thomas Smith, who studies the epidemiology of malaria at the Swiss Tropical Institute in Basel, says it may be premature to say exactly what the efficacy is based on this early data from the trial, which is still ongoing.

The lead author of the study was Jacqueline French, MD, professor of neurology and director of Translational Research & Clinical Trials Epilepsy at NYU Langone's Comprehensive Epilepsy Center.

«It will be very exciting to see if the study can move to a clinical trial soon,» said Alex Agelidis, a graduate student at UIC and co-author on the paper.

But a blood test could help researchers more easily identify people who might be good candidates for clinical trials of early interventions, says Steven Kiddle, a biostatistician at the University of Cambridge, who wasn't part of either study.

«I've been involved in clinical trials for 30 years,» says the study's lead author Bonnie Ramsey, a professor of pediatrics at the University of Washington School of Medicine in Seattle.

Helen McShane, a Professor in the Nuffield Department of Medicine at the University of Oxfordled the 2013 clinical trial who led the 2013 clinical trial, described the CSU study as «really important.»

The researchers were never able to obtain the data from the original clinical trial sponsor and in the end had to painstakingly reconstruct the study results from the information collected at each individual study site.

«By identifying and enrolling these men in clinical trials immediately, the hope is to take a prostate cancer that appears to be incurable and make it curable» stated Trevor J. Royce, MD, senior resident in the department of Radiation Oncology at BWH, and corresponding author of the study.

The study looks at data on 26 side effects from a trial of approximately 10,000 patients and suggests that cases of muscle pain and weakness are unlikely to be directly caused by statins, but may instead be due to the so - called nocebo effect, where the expectation of side effects can make patients more likely to report them.

«This study's results can have practice changing implications on how future prostate cancer trials are designed in terms of identifying the men for these studies who are at high risk for early death due to ineffective initial treatment for their prostate cancer,» stated Anthony Victor D'Amico, MD, PhD, chief, Genitourinary Radiation Oncology, Brigham and Women's Hospital and senior author of the study.

This was caused by an erroneous and incomplete search by the manufacturer for studies on the comparator therapy; no search at all was conducted in trial registries.

In an effort to find out, Stephen P. Juraschek, M.D., Ph.D., research and clinical fellow in general internal medicine at the Johns Hopkins University School of Medicine, and his colleagues used data from the DASH (Dietary Approaches to Stop Hypertension) clinical trial, a widely popular and often - cited study whose results were first published in 1997.

«It's not so much that the jury is out, but that the jury has been dismissed before the trial has begun,» says Mike Meredith, a neuroscientist at Florida State University in Tallahassee, who studies animal pheromones.

«The study results elucidate the molecular mechanisms underlying disease progression in multiple sclerosis models, providing a basis for future clinical trials to determine safety and efficacy of these chemical agents in humans with demyelinating disorders,» says Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomic Sciences at Mount Sinai and senior author of the study.